Introduction- Glaucoma is a condition where a series of progressive visual neuropathies are identified by the cavity of the optic disc, the apoptotic degradation of retinal ganglion cells (RGC), and the consequent loss of vision. Timolol maleate is a non-selective beta-adrenergic antagonist which is used mainly as an ocular preparation to treat glaucoma and ocular hypertension. Methods- Three formulations were formulated by ion activated in situ gel system. The formulation was prepared by changing the concentration of gelling system. Gellan gum concentration used were 0.5% for F1, 0.8% for F2, 1% for F3 formulation. These formulations were evaluated. Results- FTIR spectra showed all the functional groups represent in the compounds and there was no physical incompatibility observed. F1 formulation was found to have a good drug content of 87.3%. Gelling capacity was found to be good in F1 formulation. All formulations had good viscosity around 2300 to 3400 and all the formulations were found to be sterile. Conclusion- the prepared formulation F1 was sterile, with good viscosity, maximum drug concentration and with good gelling capacity.